With all the difficulties experienced by gene therapy companies in achieving systemic delivery of their gene products, Genteric Inc. is letting the human body solve its own problem. The company is commandeering gastrointestinal organs to achieve systemic delivery of gene products without delivering genes systemically.

"The GI system is designed by nature to produce proteins in large amounts," said President and CEO Martin Cleary. "Therefore, we're using gene therapy to target these organs to make therapeutic proteins."